Table 1.
Characteristics of the patients with IL28B C/C and IL28B T* genotypes.
| Characteristics | IL28B C/C | IL28B T* | All HCV patients |
|---|---|---|---|
| Number of Patients | 23 | 33 | 56 |
| Sex-Female | 6 (26.1%) | 15 (45.5%) | 21 (37.5%) |
| Age | 49.9 ± 4.4 | 47.5 ± 6.7 | 48.52 ± 5.96 |
| Race, African American (#) | 1 (4.3%) | 8 (24.2%) | 9 (16.1%) |
| Cirrhosis | 5(22.7%) | 8(25.0%) | 13 (24.1%) |
| Obesity | 13(56.5%) | 16(48.5%) | 29(51.8%) |
| Diabetes mellitus | 1(4.3%) | 5(15.2%) | 6(10.7%) |
| HCV genotype 1 | 16 (65.2%) | 27 (81.8%) | 43(76.8%) |
| Pretreatment ALT | 96 ± 59 | 111 ± 79 | 104 ± 72 |
| Pretreatment HCV RNA (IU/mL) | 5,596,354 ± 6,524,048 | 4,424,606 ± 5,295,969 | 4,893,305 ± 5,788,661 |
| High Viral Load (> 850,000 IU/mL) | 17 (77.3%) | 25 (75.8%) | 42 (76.4%) |
| No Complete EVR (p < 4.27 e-05) | 3 (13%) | 22 (68.8%) | 25 (45.5%) |
| No EVR (p < 0.005) | 1 (4.3%) | 12 (37.5%) | 13 (26.3%) |
| Sustained Virologic Response (p < 0.0022) | 15 (65.2%) | 8 (24.2%) | 23 (41.1%) |